Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

Maija Ruuth(University of Helsinki), Su Duy Nguyen(Wihuri Research Institute), Terhi Vihervaara(Zora Biosciences (Finland)), Mika Hilvo(Zora Biosciences (Finland)), Teemu D. Laajala(University of Helsinki), Pradeep Kumar Kondadi(University of Gothenburg), Anton Gisterå(Karolinska University Hospital), Hanna Lähteenmäki(Wihuri Research Institute), Tiia Kittilä(Wihuri Research Institute), Jenni Huusko(University of Eastern Finland), Matti Uusitupa(University of Eastern Finland), Ursula Schwab(University of Eastern Finland), Markku J. Savolainen(Oulu University Hospital), Juha Sinisalo(University of Helsinki), Marja‐Liisa Lokki(University of Helsinki), Markku S. Nieminen(University of Helsinki), Antti Jula(Finnish Institute for Health and Welfare), Markus Perola(University of Helsinki), Seppo Ylä‐Herttuala(University of Eastern Finland), Lawrence L. Rudel(Wake Forest University), Anssi Öörni(Åbo Akademi University), Marc Baumann(University of Helsinki), Amos Baruch, Reijo Laaksonen(Tampere University), Daniel F.J. Ketelhuth(Karolinska University Hospital), Tero Aittokallio(University of Helsinki), Matti Jauhiainen(Finnish Institute for Health and Welfare), Reijo Käkelä(University of Helsinki), Jan Borén(University of Gothenburg), Kevin Jon Williams(University of Gothenburg), Petri T. Kovanen(Wihuri Research Institute), Katariina Öörni(University of Helsinki)
European Heart Journal
May 21, 2018
Cited by 183Open Access
Full Text

Abstract

Aims: Low-density lipoprotein (LDL) particles cause atherosclerotic cardiovascular disease (ASCVD) through their retention, modification, and accumulation within the arterial intima. High plasma concentrations of LDL drive this disease, but LDL quality may also contribute. Here, we focused on the intrinsic propensity of LDL to aggregate upon modification. We examined whether inter-individual differences in this quality are linked with LDL lipid composition and coronary artery disease (CAD) death, and basic mechanisms for plaque growth and destabilization. Methods and results: We developed a novel, reproducible method to assess the susceptibility of LDL particles to aggregate during lipolysis induced ex vivo by human recombinant secretory sphingomyelinase. Among patients with an established CAD, we found that the presence of aggregation-prone LDL was predictive of future cardiovascular deaths, independently of conventional risk factors. Aggregation-prone LDL contained more sphingolipids and less phosphatidylcholines than did aggregation-resistant LDL. Three interventions in animal models to rationally alter LDL composition lowered its susceptibility to aggregate and slowed atherosclerosis. Similar compositional changes induced in humans by PCSK9 inhibition or healthy diet also lowered LDL aggregation susceptibility. Aggregated LDL in vitro activated macrophages and T cells, two key cell types involved in plaque progression and rupture. Conclusion: Our results identify the susceptibility of LDL to aggregate as a novel measurable and modifiable factor in the progression of human ASCVD.


Related Papers